261 related articles for article (PubMed ID: 38203758)
41. Consensus mutagenesis approach improves the thermal stability of system x
Oda K; Lee Y; Wiriyasermkul P; Tanaka Y; Takemoto M; Yamashita K; Nagamori S; Nishizawa T; Nureki O
Protein Sci; 2020 Dec; 29(12):2398-2407. PubMed ID: 33016372
[TBL] [Abstract][Full Text] [Related]
42. A negative correlation between expression profiles of runt-related transcription factor-2 and cystine/glutamate antiporter xCT subunit in ovariectomized mouse bone.
Uno K; Takarada T; Nakamura Y; Fujita H; Hinoi E; Yoneda Y
J Pharmacol Sci; 2011; 115(3):309-19. PubMed ID: 21325781
[TBL] [Abstract][Full Text] [Related]
43. Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1.
Zhang Y; Koppula P; Gan B
Cell Cycle; 2019 Apr; 18(8):773-783. PubMed ID: 30907299
[TBL] [Abstract][Full Text] [Related]
44. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.
Liu L; He J; Sun G; Huang N; Bian Z; Xu C; Zhang Y; Cui Z; Xu W; Sun F; Zhuang C; Man Q; Gu S
Clin Transl Med; 2022 May; 12(5):e778. PubMed ID: 35522946
[TBL] [Abstract][Full Text] [Related]
45. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance.
Lim JKM; Delaidelli A; Minaker SW; Zhang HF; Colovic M; Yang H; Negri GL; von Karstedt S; Lockwood WW; Schaffer P; Leprivier G; Sorensen PH
Proc Natl Acad Sci U S A; 2019 May; 116(19):9433-9442. PubMed ID: 31000598
[TBL] [Abstract][Full Text] [Related]
46. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer.
Hong T; Lei G; Chen X; Li H; Zhang X; Wu N; Zhao Y; Zhang Y; Wang J
Redox Biol; 2021 Jun; 42():101928. PubMed ID: 33722571
[TBL] [Abstract][Full Text] [Related]
47. A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options.
Criscuolo D; Morra F; Celetti A
Explor Target Antitumor Ther; 2022; 3(5):570-581. PubMed ID: 36338517
[TBL] [Abstract][Full Text] [Related]
48. Antisense lncRNA As-SLC7A11 suppresses epithelial ovarian cancer progression mainly by targeting SLC7A11.
Yuan J; Liu Z; Song R
Pharmazie; 2017 Jul; 72(7):402-407. PubMed ID: 29441937
[TBL] [Abstract][Full Text] [Related]
49. Cystine-glutamate antiporter deletion accelerates motor recovery and improves histological outcomes following spinal cord injury in mice.
Sprimont L; Janssen P; De Swert K; Van Bulck M; Rooman I; Gilloteaux J; Massie A; Nicaise C
Sci Rep; 2021 Jun; 11(1):12227. PubMed ID: 34108554
[TBL] [Abstract][Full Text] [Related]
50. SLC7A11/xCT in cancer: biological functions and therapeutic implications.
Lin W; Wang C; Liu G; Bi C; Wang X; Zhou Q; Jin H
Am J Cancer Res; 2020; 10(10):3106-3126. PubMed ID: 33163260
[TBL] [Abstract][Full Text] [Related]
51. Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells.
Linher-Melville K; Haftchenary S; Gunning P; Singh G
Mol Cell Biochem; 2015 Jul; 405(1-2):205-21. PubMed ID: 25896132
[TBL] [Abstract][Full Text] [Related]
52. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
Shin CS; Mishra P; Watrous JD; Carelli V; D'Aurelio M; Jain M; Chan DC
Nat Commun; 2017 Apr; 8():15074. PubMed ID: 28429737
[TBL] [Abstract][Full Text] [Related]
53. Gigantol exerts anti-lung cancer activity by inducing ferroptosis via SLC7A11-GPX4 axis.
Chen P; Lv X; Zheng Z
Biochem Biophys Res Commun; 2024 Jan; 690():149274. PubMed ID: 37995455
[TBL] [Abstract][Full Text] [Related]
54. Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc- protects from oxidative glutamate toxicity.
Lewerenz J; Klein M; Methner A
J Neurochem; 2006 Aug; 98(3):916-25. PubMed ID: 16771835
[TBL] [Abstract][Full Text] [Related]
55. Mutant p53 Mediates Sensitivity to Cancer Treatment Agents in Oesophageal Adenocarcinoma Associated with MicroRNA and SLC7A11 Expression.
Eichelmann AK; Mayne GC; Chiam K; Due SL; Bastian I; Butz F; Wang T; Sykes PJ; Clemons NJ; Liu DS; Michael MZ; Karapetis CS; Hummel R; Watson DI; Hussey DJ
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074015
[No Abstract] [Full Text] [Related]
56. Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system xc-.
Bassi MT; Gasol E; Manzoni M; Pineda M; Riboni M; Martín R; Zorzano A; Borsani G; Palacín M
Pflugers Arch; 2001 May; 442(2):286-96. PubMed ID: 11417227
[TBL] [Abstract][Full Text] [Related]
57. Formyl-Peptide Receptor 2 Signaling Modulates SLC7A11/xCT Expression and Activity in Tumor Cells.
Pecchillo Cimmino T; Punziano C; Panico I; Petrone Z; Cassese M; Faraonio R; Barresi V; Esposito G; Ammendola R; Cattaneo F
Antioxidants (Basel); 2024 Apr; 13(5):. PubMed ID: 38790657
[TBL] [Abstract][Full Text] [Related]
58. Slc7a11 (xCT) protein expression is not altered in the depressed brain and system xc- deficiency does not affect depression-associated behaviour in the corticosterone mouse model.
Demuyser T; Deneyer L; Bentea E; Albertini G; Femenia T; Walrave L; Sato H; Danbolt NC; De Bundel D; Michotte A; Lindskog M; Massie A; Smolders I
World J Biol Psychiatry; 2019 Jun; 20(5):381-392. PubMed ID: 28882088
[No Abstract] [Full Text] [Related]
59. IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-.
Yang Y; Yee D
Cancer Res; 2014 Apr; 74(8):2295-305. PubMed ID: 24686172
[TBL] [Abstract][Full Text] [Related]
60. Redox-dependent AMPK inactivation disrupts metabolic adaptation to glucose starvation in xCT-overexpressing cancer cells.
Lee Y; Itahana Y; Ong CC; Itahana K
J Cell Sci; 2022 Aug; 135(15):. PubMed ID: 35775474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
